Aslan Pharmaceuticals Limited's Comment on Competition and Industry Peers
The company faces competition from existing and potential therapies. It co-owns certain intellectual property with CSL Limited, and these co-owners may license rights to third parties, including competitors, who could develop competing products and technologies. The company may require cooperation from co-owners to license or enforce patents, which may not be granted, potentially impacting its competitive position. Additionally, the company relies on trade secret protection and confidentiality agreements to maintain its competitive advantage.
May 2, 2024
ASLAN Pharmaceuticals Expands Collaboration with Zenyaku to Investigate Eblasakimab s Unique Biology in Comparison to Other BiologicsMay 2, 2024 ASLAN Pharmaceuticals (Nasdaq: ASLN) has recently announced an extension of its research collaboration agreement with Zenyaku Kogyo Co., Ltd. (Zenyaku), aiming to delve deeper into the distinct mechanism of action exhibited by their drug, eblasakimab, compared to other biologic therapies for atopic dermatitis (AD) such as dupilumab and lebrikizumab.ASLAN Pharmaceuticals, a clinical-stage biopharmaceutical company specializing in immunology, focuses on developing innovative treatments that have the potential to transform the lives of patients. The company s partner...
March 11, 2024
ASLAN Pharmaceuticals, a leading biopharmaceutical company focused on immunology, has recently provided an important update regarding its ongoing TREK-DX trial. The study aims to evaluate the efficacy and safety of eblasakimab in patients with moderate-to-severe atopic dermatitis (AD), who have prior experience with the medication dupilumab. This article aims to outline the facts surrounding the study update and assess its potential impact on ASLAN Pharmaceuticals.Facts:1. Enrolling Patients: ASLAN Pharmaceuticals has commenced patient enrollment in the United States for the TREK-DX trial, under an updated protocol. This implies that the study is progressing as per plan and signifies an important milestone f...
March 6, 2024
ASLAN Pharmaceuticals Announces Positive Translational Data on Eblasakimab in COPD and Appoints Leading Respiratory Experts as Scientific AdvisorsSan Mateo, Calif. and Singapore March 06, 2024 ASLAN Pharmaceuticals Ltd. (Nasdaq: ASLN), a clinical-stage biopharmaceutical company focused on immunology, has unveiled new promising translational data from a head-to-head study of eblasakimab versus dupilumab in a human tissue model of chronic obstructive pulmonary disease (COPD). This data further reinforces the potential of eblasakimab as a biologic therapy for COPD. Additionally, ASLAN Pharmaceuticals has appointed renowned respiratory experts, Dr. Ramaswamy Krishnan and Dr. Reynold Panettieri Jr., to its Sc...
Publicly Traded Peers of Aslan Pharmaceuticals Limited
Sources:
Aslan Pharmaceuticals Limited’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Aslan Pharmaceuticals Limited versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
